Personalized cancer treatment 2.0: new combination strategy developed


Tumors often comprise groups of cancer cells that show differential drug sensitivities. This is one of the reasons that initially effective treatments usually do not lead to long-term benefit in patients. Researchers from the Netherlands Cancer Institute, in collaboration with the international biotechnology company Genmab A/S, have now developed a new strategy to tackle this problem.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.